Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Appointment of New Director

31st Jul 2025 07:00

RNS Number : 2830T
BioPharma Credit PLC
31 July 2025
 

31 July 2025

 

BIOPHARMA CREDIT PLC

(THE "COMPANY")

Appointment of New Director

 

The Board of Directors of the Company, as part of its proactive succession planning, is pleased to announce the appointment of Nigel Reynolds as a non-executive Director with effect from 1 January 2026, following his retirement from PwC on 31 December 2025. Mr Reynolds will, after a transition period, take over as chair of the Company's Audit and Risk committee.

Mr Reynolds has 34 years of accounting and finance experience advising both listed and private companies. He has been a partner at PwC for 20 years specialising in audit, transaction services and capital markets work. During his time at PwC, he led its London Assurance practice for 5 years, led the private equity portfolio company practice and was the relationship partner for various UK listed and international companies including companies in healthcare and investment trusts. Over his career he has also advised companies on strategy, M&A, internal audit and tax and has overseen technology, sustainability, and other large projects for PwC clients.

There are no other details required to be disclosed under LR 9.6.13R (1) to (6) of the Financial Conduct Authority Listing Rules.

 

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0)20 7466 5000

[email protected]

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZGFNRGGGKZM

Related Shares:

Biopharma Cred.
FTSE 100 Latest
Value9,068.58
Change-64.23